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Abstract
Background: We aimed to establish levels of consumer involvement in randomised controlled trials (RCTs), meta-
analyses and other studies carried out by the UK Medical Research Council (MRC) Clinical Trials Unit across the
range of research programs, predominantly in cancer and HIV.
Methods: Staff responsible for studies that were included in a Unit Progress Report (MRC CTU, April 2009) were
asked to complete a semi-structured questionnaire survey regarding consumer involvement. This was defined as
active involvement of consumers as partners in the research process and not as subjects of that research. The
electronic questionnaires combined open and closed questions, intended to capture quantitative and qualitative
information on whether studies had involved consumers; types of activities undertaken; recruitment and support;
advantages and disadvantages of involvement and its perceived impact on aspects of the research.
Results: Between October 2009 and April 2010, 138 completed questionnaires (86%) were returned. Studies had
been conducted over a 20 year period from 1989, and around half were in cancer; 30% in HIV and 20% were in
other disease areas including arthritis, tuberculosis and blood transfusion medicine. Forty-three studies (31%) had
some consumer involvement, most commonly as members of trial management groups (TMG) [88%]. A number of
positive impacts on both the research and the researcher were identified. Researchers generally felt involvement
was worthwhile and some felt that consumer involvement had improved the credibility of the research. Benefits in
design and quality, trial recruitment, dissemination and decision making were also perceived. Researchers felt they
learned from consumer involvement, albeit that there were some barriers.
Conclusions: Whilst most researchers identified benefits of involving consumers, most of studies included in the
survey had no involvement. Information from this survey will inform the development of a unit policy on
consumer involvement, to guide future research conducted within the MRC Clinical Trials Unit and beyond.
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Background
The concept of consumer involvement in clinical
research is not a new one. In 1998 the UK Medical
Research Council (MRC) published guidelines on good
practice in clinical trials [1] which recommended consu-
mer involvement, specifically within clinical trial steering
committees (TSC) and to assist in the development of
patient information material. Two UK Department of
Health publications regarding clinical research within
the NHS in England [2,3] recognised the value of
consumer involvement, stating that patients and the
public must be involved in all stages of the research
process. Internationally, a number of initiatives that sup-
port consumer involvement in healthcare research have
been established, for example the US National Institutes
for Health (NIH) Directors Council of Public Represen-
tatives and the Cochrane Collaboration Consumer Net-
work. Such initiatives have improved awareness and
potentially led to an increased acceptance of involve-
ment by the research community.
In the UK, surveys have been conducted to gauge the
extent and type of participation of consumers in UK* Correspondence: cv@ctu.mrc.ac.uk
MRC Clinical Trials Unit, London, UK
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National Health Service (NHS) research [4] and UK
clinical trials units that were conducting randomised
controlled trials [5]. In this second survey, researchers
contacted 103 clinical trials units in the UK. Of the 62
eligible responses received, 23 units reported that consu-
mers had already been involved in their work. Most
were positive about this involvement. 17 units planned
to involve consumers. 15 centres had no plans to
involve consumers, but only four of these considered
such involvement irrelevant. Trials units were then con-
tacted to seek further information about involvement in
48 individual trials. Again, responses were mostly posi-
tive. Consumers were reported to have helped refine
research questions, improve the quality of patient infor-
mation, and make the trial more relevant to the needs
of patients.
The MRC Clinical Trials Unit (CTU) designs, runs, ana-
lyses and reports high quality randomised controlled trials
(RCTs), meta-analyses and other clinical studies in a vari-
ety of healthcare areas, primarily cancer, HIV and other
infectious diseases. In 2008, a Consumer Involvement
Group was established at the CTU to support involvement
across the breadth of its research. The Group, members of
which are all employees of the MRC CTU and include a
statistician, trial management staff and a systematic
reviewer, was aware of some research areas and individual
studies in which there had been considerable consumer
involvement. However it was felt that there was a lack of
consistency in the approach to involvement between
research programmes in different disease areas and study
types within the CTU. Therefore the Group set out to
more formally assess both past and current levels of invol-
vement across all CTU research studies, with the primary
aims of:
(1) Establishing the extent of consumer involvement
throughout the CTU
(2) Evaluating CTU researchers perceptions of the
impact of involvement
(3) Developing guidance for researchers to improve
consumer involvement in clinical studies at the CTU
(4) Informing consumer involvement in clinical
research more widely
Methods
We used the term ‘consumer involvement’ in line with
the UK National Cancer Research Institute (NCRI),
since the initial work of the CTU Consumer Involve-
ment Group was confined to the Unit’s cancer trials.
Our definition of consumer involvement, which was
based on the INVOLVE definition of public involvement
http://www.invo.org.uk/, was the active involvement of
consumers (i.e. patients, carers or family members,
health service users, patient representatives or members
of groups or organisations that represent those affected
by the condition being researched) as partners in the
research process and not as subjects of that research.
For example, patients or carers as members of trial
management groups (TMG; see Additional File 1: Trial
Management Group Information Pack); involvement of
a patient organisation in the planning of a trial, or
patients contributing to the development of patient
information materials.
The semi-structured survey questionnaire (see Addi-
tional File 2) was developed by members of the CTU
Consumer Involvement Group. It combined a mixture
of open and closed questions designed to capture both
quantitative and qualitative information on whether or
not the studies had involved consumers; how consumers
had been identified and supported; the types of activities
undertaken; researchers’ perspectives on the benefits
and challenges of involvement and the perceived impact
of consumer involvement on their research. For catego-
rical questions, a list of possible categories was devel-
oped by the Consumer Involvement Group based on
their own experiences of consumer involvement and
knowledge of external examples of consumer involve-
ment, from the medical literature or from other research
units. For each categorical question, respondents were
also given an ‘other’ option, which they were asked to
specify. Prior to wider distribution, members of the
Group tested the logic of the questionnaire design and
data capture using either real examples from their own
work or dummy data.
The sampling frame used for the survey was all CTU-led
clinical research studies that had been included in CTU
progress report (April 2009). The report outlined all
research, predominantly RCTs, non-randomised trials and
systematic reviews across all programmes of research at
the CTU, carried out over a six year period (January 2003
to January 2009). The studies represented different stages
of research from early development through to studies
that had been completed and reported. The lead members
of staff for each study (including clinicians, senior clinical
trialists, statisticians, systematic reviewers and epidemiolo-
gists) most of whom were based at the CTU, were con-
tacted by email and asked to complete the online survey
(http://SurveyMonkey.com, LLC, Palo Alto, California,
USA) by following a direct link within the email. Data col-
lection took place between October 2009 and April 2010,
with data from the survey captured electronically. Mem-
bers of staff who did not complete the survey by the first
deadline received two further requests. After this, non-
responders were replaced with alternative members of
staff connected with the study wherever possible. Follow-
ing data collection, responses for each study were matched
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with the study start date, defined as the date the trial
opened to recruitment or the protocol date for the sys-
tematic reviews.
The proportion of studies with consumer involvement;
roles undertaken by consumers and researchers’ motiva-
tions for initiating involvement were analysed using
STATA 11.1. Analyses using the study start dates were
also conducted to assess whether consumer involvement
had changed over time and also whether there was a dif-
ference in the extent of consumer involvement between
ongoing and completed research. Ongoing research was
defined as research that was either in start up, actively
enrolling or in follow-up. Completed research was
defined as research that was published; completed but
not yet published or had been stopped or suspended.
Free text answers to questions regarding the researchers’
perceptions of the impact of involvement on the research;
the impact of involvement on the individual researcher
and on challenges or problems faced with involvement
were collated into themes by individual members of the
Consumer Involvement Group. Major themes were subse-
quently identified through discussion among the Group
until consensus was reached. Categories emerging from
the written text answers from responders were then iden-
tified within these major themes.
Results
At the outset, 34 lead CTU researchers were identified as
responsible for the 160 studies included in the survey.
However, alternative and additional responders were iden-
tified during the data collection process such that, in April
2010, when the survey was closed, 138 (86%) completed
questionnaires had been returned by 35 named responders
(128 questionnaires, 93%) plus 10 further anonymous
responders (7%). These studies had start dates ranging
from 1989 - 2009, and included 93 RCTs (67%), and 23
systematic reviews (17%), 15 non-randomised trials (11%)
and 7 epidemiological or observational studies (5%). There
were similar numbers of completed (69) and ongoing (68)
studies (the status of one further trial was unknown).
Sixty-nine studies (50%) were in cancer; 42 (30%) were in
HIV and 27 (20%) were in other disease areas including
arthritis, tuberculosis and blood transfusion medicine, giv-
ing a good representation of the work of the CTU.
Extent of Consumer Involvement at MRC CTU
Of the 138 responses, 43 (31%) studies had involved con-
sumers and 64 studies (46%) had no involvement. For the
remaining 31 studies (23%) the respondents gave no
answer (23 studies) or were uncertain whether there had
been involvement (8 studies). For these 8 studies, the
most common reasons given were that another organisa-
tion coordinated the project and the respondent did not
know the local arrangements (n = 3) or because they had
only recently become involved in the study and did not
know whether there had been any involvement previously
(n = 2). Of the 43 studies that involved consumers, 34
(79%) were RCTs.
When studies were grouped by start dates (Figure 1), of
the 8 studies that started before 1995, almost all of which
are now completed (90%), only one study had consumer
involvement. For the 41 studies initiated between 2005
and 2009 (73% completed), 25 (61%) had consumer
involvement. Indeed all of the RCTs initiated in 2009
(n = 4) had consumer involvement. There was also a
higher frequency of consumer involvement in ongoing
studies (27/68, 40%) than in completed studies (16/55,
23%; p = 0.037).
Reasons for involving consumers
CTU researchers were asked to select their reasons for
involving consumers (Figure 2). The most common rea-
son selected (29 studies, 73%) was that researchers
thought it was the right thing to do. Responders cited
other reasons for involvement in 11 studies (26%),
included learning more about the disease or population
(2 studies); that involvement was essential or necessary in
relation to recruitment, ensuring the appropriateness of
research materials or giving guidance on issues (3 stu-
dies) and because funding bodies recommended involve-
ment, without it being a requirement (3 studies). Three
further respondents did not know what reasons had lead
to involvement in their studies.
How consumers were involved in MRC CTU studies
Researchers were asked about how many consumers had
been involved in their studies, how they had been identi-
fied or recruited and what types of activities they had
taken part in. Most studies involved less than three con-
sumers (31 studies, 72%) with 14 studies involving only
one consumer. However, some involved considerably
more, for example, the Micobicides Development Pro-
gramme (MDP) involved a large number (> 100) of
patient and community representatives in focus groups
to inform the study design. Overall, consumers were
identified from a variety of sources, although they were
often already known to a member of the research group
(n = 31, 72%), for example as current or former patients
of the clinical investigators, or through previous involve-
ment in a research study. Only one study had actively
attempted to recruit consumers by advertising the
opportunity.
Consumer involvement in CTU studies was most
commonly as part of a trial management group (TMG)
or similar study advisory or steering group (35/43,
[88%], Figure 3). Consumers in these studies undertook
a variety of activities, for example, writing or comment-
ing on patient information sheets (24 studies, 67%); trial
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promotion activities (19 studies, 54%); aspects of proto-
col development (14 studies, 40%) or interpreting and
disseminating the results (9 studies, 26%).
Perceived impacts of Consumer Involvement
Table 1 gives a summary of the responses to semi-struc-
tured questions relating to the respondents perceptions
of benefits of consumer involvement; problems with
involvement; the impact of involvement on the study
and also on the individual researcher for those studies
with consumer involvement. Whilst we had intended to
analyse the results for the individual questions sepa-
rately, there was significant overlap between the
responses for questions relating to benefits and impacts.
Therefore, themes were identified from the combined
responses to these three questions (n = 90). The indivi-
dual responses were then grouped within these themes.
The six major categories emerging from the textual
responses to these questions were:
i. Improvements in study design and recruitment
Researchers running studies that had involved consu-
mers felt that patients’ experiences, for example, of
treatments being used in the trials, were very valuable in
trial design and provided insights into why patients may
(or may not) consent to a study. Researchers felt that
this potentially resulted in improved acceptability of the
study designs to patients considering entering the trial,
which may have also impacted indirectly to improve
recruitment, for example:
TRISST: A Trial of imaging and schedule in semi-
noma testis: http://www.ctu.mrc.ac.uk/research_ar-
eas/study_details.aspx?s=40 Consumers contributed
to TMG discussion about recruitment, “specifically
ideas as to why certain patients would consent to
enter TRISST which offers different surveillance
schedules to detect relapse rather than opt for adju-
vant chemotherapy”
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Figure 1 Consumer involvement by trial start year. Based on 103 trials (31 studies with unknown involvement status and 4 studies with
unknown start dates excluded).
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STALWART trial [6]: An RCT of Aldesleukin with
or without anti-retroviral therapy in patients with
HIV-1 Infection. Consumer involvement through a
Community Advisory Board, representing interna-
tional trial centres “ensured an active connection to
diverse people in their local communities” and
“ensured that the community’s needs and concerns
were expressed to researchers”. This enabled
researchers to better understand issues that may
impact on research.
FORTE study [7]: A RCT evaluating treatment combi-
nations in individuals with HIV-1 infection. “It was dif-
ficult to tell the precise impact of consumer
involvement” but the researcher felt that it had “helped
recruitment” and regarding changes to the trial design,
found that consumers were “helpful in discussions
about what would be acceptable to participants”
PRION-1 trial [8]: A patient preference study evaluat-
ing the activity and safety of quinacrine in human
prion disease. “Consumers certainly had a lot of input
into study design and reviewed the protocol” with the
results that, “Trial design was far more acceptable to
patients and their families and uptake was very high
(~76% of eligible patients joined)”
MDP301 study: A randomised, double-blind study
to evaluate microbicide gels for the prevention of
vaginally acquired HIV infection. http://www.ctu.
mrc.ac.uk/research_areas/study_details.aspx?s=16
“Consumer involvement was absolutely necessary to
ensure the research materials were appropriate and
to recruit people to the studies”. Feedback (from
consumers) meant that “clinic procedures could be
streamlined, and recruitment strategies amended”.
Without involvement of consumers the researchers
felt that “recruitment and retention targets could not
have been met”.
CHAPAS-1 [9]: A study of the pharmacokinetics
and adherence to simple antiretroviral regimens for
children with HIV in Africa “It helped to get the
carers’ perspective on the research and to ensure
that all the research was appropriate and acceptable
to the local population.”
ii. Improvements in study promotion and dissemination
Researchers also felt that where consumers had been
involved in various trial promotion activities, there may
also have been an impact on recruitment (Box 2). For
example, consumers helped to promote specific trials or
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Figure 2 Reasons for involving consumers. Based on 43 studies with consumer involvement.
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educate others more generally about clinical trials
through involvement in patient support groups or net-
works. In addition, researchers at the CTU had involved
consumers in the dissemination of their research find-
ings. For example, identifying additional routes for disse-
mination e.g. patient groups or networks and helping to
prepare lay summaries of the scientific findings, for
example:
RADICALS: Radiotherapy and androgen deprivation
in combination after local surgery. A randomised
controlled trial in prostate cancer http://www.ctu.
mrc.ac.uk/research_areas/study_details.aspx?s=28
Consumer involvement provided a direct “connection
to patient communities” for promotion of the trial
PREDICT: A randomised controlled trial of contin-
uous positive airway pressure treatment in older
people with obstructive sleep apnoea/hypopnoea
syndrome http://www.ctu.mrc.ac.uk/research_areas/
study_details.aspx?s=81 The consumers (who were
part of the trial steering committee) helped in the
development of an educational YouTube video about
obstructive sleep apnoea
MDP301 study: A randomised, double-blind study
to evaluate microbicide gels for the prevention of
vaginally acquired HIV infection. http://www.ctu.
mrc.ac.uk/research_areas/study_details.aspx?s=16
Consumers were involved in “Peer education about
the trial, about adherence (to the study treatment)
and HIV prevention in general”
DART [10]: Development of AntiRetroviral Therapy
in Africa - A randomised trial of monitoring practice
and structured treatment interruptions in the man-
agement of antiretroviral therapy in adults with HIV
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Figure 3 Activities undertaken by consumers. Based on 43 CTU studies with consumer involvement.
Table 1 Summary of responses to semi-structured questions from 43 studies with consumer involvement
Question Responses (n)
No Yes - no reason given Yes - reason given Did not respond
1. Were there any benefits of consumer involvement? 1 2 37 3
2. Were there any impacts of involvement on the research study? 11 3 26 3
3. Were there any impacts of involvement on the researcher? 10 3 27 3
4. Were there any problems of involving consumers? 28 3 9 3
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infection in Africa http://www.ctu.mrc.ac.uk/dart/
The researcher stated that involving consumers,
“hugely aided dissemination” at the end of the trial,
as well as having been important in “uptake and
acceptance” at the start of the trial. They also com-
mented that consumers had been very useful in
helping to deal with some negative reactions to the
trial at one point.
iii. Improvements in study documentation
Furthermore, involvement of consumers in studies was
felt to have helped to improve the study documentation.
Researchers at the CTU identified several stages of their
research where consumers had this sort of impact,
including protocol development, writing patient infor-
mation and also involvement in writing the study papers
and other documents. In one study, consumers had also
been involved in a funding application, for example:
TRISST A Trial of imaging and schedule in semi-
noma testis http://www.ctu.mrc.ac.uk/research_ar-
eas/study_details.aspx?s=40 Consumer involvement
was beneficial in “wording for our patient informa-
tion sheet update during a major protocol amend-
ment submitted to ethics”
COIN [11]: An RCT comparing continuous che-
motherapy plus cetuximab, or intermittent chemother-
apy with standard chemotherapy in the treatment of
patients with metastatic colorectal cancer http://www.
ctu.mrc.ac.uk/research_areas/study_details.aspx?s=10
The consumers “helped remind us of the patient per-
spective on lots of issues. They also helped us with the
trial launches and with patient information - getting
the patient perspective on the lay summary was really
helpful”
PRION Systematic Review [12]: Treatments for
human prion disease: a systematic review http://
www.ctu.mrc.ac.uk/research_areas/study_details.
aspx?s=56 “It was useful to have someone with a
non-scientific perspective commenting on the manu-
script, for example questioning results or processes
that are often taken for granted. They were also very
helpful when preparing a lay summary of the scienti-
fic findings, for dissemination to a wider audience.”
DOMINO-AD [13]: Donepezil and Memantine in
moderate to severe Alzheimer’s disease http://www.
ctu.mrc.ac.uk/research_areas/study_details.aspx?s=50
“The (consumer) members who sit on our commit-
tee are actively engaged with the trial and offer very
useful comments on how patients/carers may view
the trial and trial materials. They have also made a
valuable contribution to our application for addi-
tional funding.”
iv. Improvements in decision making
Consumers were also involved in making important
decisions about the study, or in helping researchers to
reach what they felt to be better decisions. For example,
in one trial, consumers contributed to a decision regard-
ing continuing the use of a particular drug in the trial
design. In a systematic review, consumer input had led
the research group to undertake a related research pro-
ject when the review was unable to address an issue that
was important to the consumers, for example:
STAMPEDE: Systemic Therapy in Advancing or
Metastatic Prostate Cancer: Evaluation of Drug Effi-
cacy http://www.ctu.mrc.ac.uk/research_areas/
study_details.aspx?s=34 “Just before the trial
launched, there were problems with one of the trial
drugs; STAMPEDE was investigating celecoxib and a
drug in the same family (cox-2 inhibitors), rofecoxib,
had shown cardiac problems in another trial in a
completely different context. All trials involving cox-
2 inhibitors were stopped indefinitely. The TMG
had to decide whether to drop this drug and con-
tinue with the remaining arms or to wait until there
was further information about these agents. Our
consumers were absolutely vital in helping us come
to a good decision (which was to wait a while and
keep the drug in the trial)”
IPDMA in cervical cancer [14]: Concomitant che-
moradiotherapy versus radiotherapy alone for cervi-
cal cancer: a systematic review and meta-analysis of
individual patient data. http://www.ctu.mrc.ac.uk/
research_areas/study_details.aspx?s=45 “As a result
of involving the consumers, we decided to become
involved in a subsequent piece of research that we
hoped would allow us to provide information on late
treatment effects. I’m not sure we would have done
so if the consumers hadn’t been involved. Our con-
sumers are also involved in helping us to decide
how best to involve others in our future meta-
analyses”
N-Alive: Can we stop heroin injectors dying from an
overdose if we give them a drug called Naloxone to
carry around with them when they leave prison?
http://www.ctu.mrc.ac.uk/research_areas/study_de-
tails.aspx?s=80 “Focus group members helped to
decide on the information inserts and the wallet to
be used for dissemination of the Naloxone in the
trial.”
v. Increased confidence in the study
Consumer involvement enabled researchers to feel more
confident that the studies they were conducting were
targeting and responding to consumer needs. They
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could feel more certain that they were appropriately
dealing with patients’ concerns and addressing the most
relevant issues by patients and their families. Research-
ers also indicated that working with people who had
first hand experience of a disease enabled them to better
understand the condition or treatments being studied
and to put the research into context, for example:
QUARTZ: Does radiotherapy improve patient’s quality
of life when lung cancer has spread to the brain?
http://www.ctu.mrc.ac.uk/research_areas/study_details.
aspx?s=27 “I think it gave the trial much greater cre-
dence, but if I’m totally honest, I can’t think of any
major things that would not have happened if we had
not had consumer involvement. However, the consu-
mer was extremely positive about being involved, and
spoke to many consumer groups about this.”
CHORUS: A large randomised trial to determine the
impact of timing of surgery and chemotherapy in
patients with ovarian cancer. http://www.ctu.mrc.ac.uk/
research_areas/study_details.aspx?s=9 The researcher
reported that consumer involvement “helped endorse
the relevance and credibility of the trial” and that
resulted in them having “more confidence in the rele-
vance of the research”
MIA001 [15]: A randomised trial to assess the safety
of a vaginal microbicide gel versus vehicle placebo in
Uganda http://www.ctu.mrc.ac.uk/research_areas/
study_details.aspx?s=136 A researcher from the trial
team felt that there had been a direct impact of
involving consumers in terms of the team “being
more confident that we were appropriately targeting
and responding to consumer needs”
DART [10]: Development of AntiRetroviral Therapy
in Africa - A randomised trial of monitoring practice
and structured treatment interruptions in the man-
agement of antiretroviral therapy in adults with HIV
infection in Africa http://www.ctu.mrc.ac.uk/dart/
The researcher felt that there had been “Huge bene-
fits in terms of credibility and acceptance” from con-
sumer involvement.
PRION Systematic Review [12]: Treatments for
human prion disease: a systematic review http://
www.ctu.mrc.ac.uk/research_areas/study_details.
aspx?s=56 The researcher said that working with the
consumer had “made me think much more about
the impact of the disease and potential treatments,
as well as attitudes of the scientific community
towards patients and their carers, and gave me a
new perspective on the work I was doing.”
vi. Challenges for researcher in involving consumers
Although the majority of responses indicated that
researchers felt positive about their experiences of
involving consumers, there were some challenges. These
included additional resources or time required to
involve consumers; consumers becoming too unwell
during the course of the research to continue their
involvement or having difficulties attending meetings.
Some researchers also reported that they had found it
difficult to know what to expect from the consumers
and did not know where to go for help or advice. Most
of those who had involved consumers indicated that
they had received no training on how best to involve
consumers in their studies and many indicated that
some kind of support (e.g. guidelines or mentoring) may
have been helpful.
Discussion
Although we surveyed more than 40 individual CTU
researchers spanning 160 projects and had a high
response rate (86%), we found that only 43 studies
(31%) had involved consumers. This is a slight increase
on previously reported rates of consumer involvement
in clinical trials found in a number of previously pub-
lished surveys [4,5,16] A survey of 103 UK clinical trials
units in 2001 found that 23 (22%) were actively invol-
ving consumers [5] and a national postal survey of 900
randomly selected researchers in the UK in 2007
reported that 88 (17%) were involving consumers,
mainly as members of project steering groups; in the
design of research instruments and/or in the planning
or designing of the research methods [4]. More recently,
public involvement in applications made to the UK
National Research Ethics Service in 2010 has been
reported [16]. Of 646 applications, 95% of which
described clinical trials, only 124 applications (19%) ade-
quately demonstrated ongoing or planned public invol-
vement. For those applications with involvement, in
keeping with the results from our survey, members of
the public undertook a variety of tasks spanning all
aspects of the study, most commonly being involved in
design and dissemination. Because studies in our survey
spanned a 20-year period, we have also been able to
demonstrate an increase in involvement at MRC CTU
since the early 1990s, such that around two thirds of all
studies initiated in 2009 (100% of new RCTs) had con-
sumer involvement. The number of studies that involved
consumers seems to have increased since 2005, which
coincides with the first publication of the UK NHS
Research Governance Framework [2] which recom-
mended that researchers should actively involve consu-
mers. Subsequently, in 2007, the CTU Cancer group
launched a guidance document for consumer involve-
ment in trials (see Additional File 3). Whilst our results
do not tell us the reasons for increased consumer invol-
vement in the CTU around this time, it is likely that as
a consequence of the framework being published, there
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was a greater awareness of consumer involvement that
may have had an indirect impact on CTU researchers.
Interestingly, our results show that the majority of con-
sumers had been involved as members of committees; in
particular trial management groups often as the only con-
sumer involved in the study, which we recognise can be
difficult for the individual and may not be appropriate.
The CTU has worked with consumers who take part in
these groups to improve their experiences. This has
resulted in the production of an induction pack for new
TMG consumer members (see Additional File 1), which
has been very useful and may have broader application for
other organisations. Our results seem to indicate that, in
general, membership of such groups leads to consumers
being involved in additional trial-related activities, includ-
ing commenting on patient information or helping to
improve recruitment into studies.
Researchers generally thought that involvement was
worthwhile, perceiving benefits in trial design and qual-
ity, recruitment, dissemination and decision making.
We found that it was difficult to assess the direct
impact of consumer involvement on either the research
or the researchers. For example, where consumers had
been involved in helping to improve recruitment into a
trial, it was not possible to evaluate whether any
changes in recruitment were as a direct result of that
input or not. A Cochrane systematic review of consu-
mer involvement in clinical research [17] found very
few examples where it had been possible to draw direct
comparisons of consumer involvement with no involve-
ment. We certainly did not identify any such compari-
sons being carried out within CTU research studies.
An ongoing MRC funded research project http://www.
mrc.ac.uk/ResearchPortfolio/Grant/Record.htm?Gran-
tRef=G0902155&CaseId=16504 is currently aiming to
contribute more robust approaches to measuring the
impact of consumer involvement in clinical research.
Once such methods become available they could be
implemented in MRC CTU research to provide a better
assessment of the impact of consumer involvement.
The specific aims of this survey meant that only the
researchers, and not the consumers, were consulted.
However, opinions and feedback of consumers who have
participated in MRC CTU research, particularly in cancer
trials, has previously been sought through workshops
organised by the MRC CTU Consumer Involvement
Group. Furthermore, the authors acknowledge that some
aspects of the survey design may have limited the respon-
ders, for example forcing them to select from predefined
categories rather than giving free text responses. For
practical reasons the survey was not anonymised. This
had some advantages in that it enabled targeted remin-
ders to be sent and probably facilitated the high response
rate. However, we acknowledge that some responders
may have felt restricted in how they answered the ques-
tions given that their colleagues would collate and ana-
lyse the data.
Whilst our results suggest that the trend has been
towards increased involvement over recent years, around
one third still have no direct consumer involvement.
Recently we have tried to address this by involving a con-
sumer in the CTU Protocol Review Committee. The con-
sumer’s role is to read and comment on protocols,
focussing in particular (but not exclusively) on patient
information sheets and consent forms and more gener-
ally, contributing to discussions about all proposals, espe-
cially from the perspective of patients and/or potential
participants. This ensures that all new trial protocols
have some consumer input prior to the trial being fina-
lised. Moreover, researchers identified some barriers,
including additional time and resources needed and pro-
blems when consumers were unwell. We now aim to
identify key areas of support that researchers at the CTU
need, which we hope will guide them to effectively
involve consumers in future work. As a first step we have
recently updated guidance documents for trial staff
(Additional Files 1 and 3) which may be helpful more
broadly to those considering consumer involvement in
clinical trials and have recently been involved in the
development of guidance for researchers on patient
involvement in clinical trials for INVOLVE http://www.
invo.org.uk. We also aim to develop a CTU policy on
consumer involvement for future studies and will con-
tinue to monitor involvement across the CTU. We envi-
sage that consumer involvement in the program of
clinical trials and other clinical studies at CTU will be the
focus of this activity, with priority given to those trials
where involvement is likely to have the greatest impact,
for example those with patient centred outcomes, poten-
tially complex treatment schedules, interventions that
have had wide media coverage etc. We hope that these
measures will ensure that consumer involvement at the
CTU continues to improve and develop in our ongoing
and future research
Conclusions
Results from this survey have provided some evidence as
to the extent and nature of consumer involvement at a
large clinical trials unit. Whilst involvement has
increased over time, further improvements are neces-
sary. We would encourage those involved in the conduct
of clinical research to share their experiences of consu-
mer involvement to further expand the evidence base in
respect to impacts of involvement and so that others
may learn from them. We have also attempted to iden-
tify the ways in which this involvement is seen to have
benefited the research process. However, more robust
tools are needed to help researchers to assess the impact
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of involvement routinely and prospectively in their
studies.
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